Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude pour explorer l'efficacité du JNJ-89495120 dans le traitement du trouble dépressif majeur (Moonlight-1)

24 septembre 2026 mis à jour par: Janssen Research & Development, LLC

Une étude de preuve de concept randomisée, en double aveugle, multicentrique, contrôlée par placebo, pour évaluer l'efficacité, l'innocuité et la tolérabilité du JNJ-89495120 en monothérapie chez des participants adultes souffrant de trouble dépressif majeur (TDM)

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).

Aperçu de l'étude

Statut

Complété

Les conditions

Type d'étude

Interventionnel

Inscription (Réel)

105

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Alabama
      • Huntsville, Alabama, États-Unis, 35801
        • UAB Huntsville Regional Medical Campus
    • Arizona
      • Chandler, Arizona, États-Unis, 85224
        • Chandler Clinical Trials
      • Phoenix, Arizona, États-Unis, 85012
        • IMA Clinical Research PC Phoenix
      • Tucson, Arizona, États-Unis, 85724
        • University of Arizona
      • Tucson, Arizona, États-Unis, 85704
        • Noble Clinical Research
    • California
      • Bellflower, California, États-Unis, 90706
        • CI Trials
      • Encino, California, États-Unis, 91316
        • Wake Research PRI Encino
      • Garden Grove, California, États-Unis, 92844
        • National Institute Of Clinical Research
      • Newport Beach, California, États-Unis, 92660
        • WR-Newport Beach
      • Orange, California, États-Unis, 92866
        • ATP Clinical Research
      • Redlands, California, États-Unis, 92374
        • Anderson Clinical Research
      • San Diego, California, États-Unis, 92103
        • Artemis Institute for Clinical Research
      • San Jose, California, États-Unis, 95124
        • Lumos Clinical Research Center LLC
      • Santa Ana, California, États-Unis, 92705
        • Syrentis Clinical Research
      • Temecula, California, États-Unis, 92591
        • Inland Psychiatric Medical Group Inc
      • Walnut Creek, California, États-Unis, 94596
        • Sunwise Clinical Research
    • Colorado
      • Denver, Colorado, États-Unis, 80209
        • Mountain View Clinical Research
    • Florida
      • Fort Myers, Florida, États-Unis, 33912
        • Gulfcoast Medical Research Center
      • Hollywood, Florida, États-Unis, 33021
        • The Medici Medical Research
      • Homestead, Florida, États-Unis, 33030
        • Advanced Research Institute of Miami
      • Maitland, Florida, États-Unis, 32751
        • K2 Medical Research
      • Miami, Florida, États-Unis, 33126
        • Pharmax Research Clinic Inc
      • Miami, Florida, États-Unis, 33135
        • Wellness Research Center
      • Pembroke Pines, Florida, États-Unis, 33024
        • Best Choice Medical and Research Service
      • Tampa, Florida, États-Unis, 33629
        • Interventional Psychiatry of Tampa Bay
      • West Palm Beach, Florida, États-Unis, 33407
        • Health Synergy Clinical Research
    • Georgia
      • Atlanta, Georgia, États-Unis, 30328
        • Synexus Clinical Research US Inc
      • Decatur, Georgia, États-Unis, 30030
        • iResearch Atlanta LLC
      • Snellville, Georgia, États-Unis, 30078
        • Accelerated Clinical Research Group LLC
    • Illinois
      • Chicago, Illinois, États-Unis, 60637
        • University of Chicago Medical Center
    • Indiana
      • Indianapolis, Indiana, États-Unis, 46202
        • Indiana University IU Health
    • Louisiana
      • New Orleans, Louisiana, États-Unis, 70115
        • DelRicht Research
    • Maryland
      • Gaithersburg, Maryland, États-Unis, 20877
        • CBH Health
    • Massachusetts
      • Worcester, Massachusetts, États-Unis, 01655
        • University of Massachusetts Medical School
    • New York
      • Brooklyn, New York, États-Unis, 11229
        • Integrative Clinical Trials LLC
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45219
        • University of Cincinnati
      • Cincinnati, Ohio, États-Unis, 45215
        • Patient Priority Clinical Sites LLC
      • Columbus, Ohio, États-Unis, 43210
        • OSU Department of Psychiatry and Behavioral Health
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73116
        • Paradigm Research Professionals, LLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19104
        • University of Pennsylvania
    • South Carolina
      • North Charleston, South Carolina, États-Unis, 29405
        • Coastal Carolina Research Center
    • Texas
      • McKinney, Texas, États-Unis, 75071
        • Revival Research Institute LLC
    • Utah
      • Clinton, Utah, États-Unis, 84015
        • Alpine Research Organization
    • Washington
      • Everett, Washington, États-Unis, 98201
        • Core Clinical Research

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 64 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
  • Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
  • Were first diagnosed with depression before the age of 55
  • Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
  • Have taken 0, 1, or 2 treatments for depression in your current episode
  • Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m^2) at screening

Exclusion Criteria:

  • Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
  • Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
  • Post-traumatic stress disorder within the past three years of screening
  • Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
  • History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
  • Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Arm 1: JNJ-89495120 Dose A

Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study.

JNJ-89495120 will be administered.

Expérimental: Arm 2: JNJ-89495120 Dose A and Dose B

Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study.

JNJ-89495120 will be administered.

Comparateur placebo: Arm 3: Placebo Group

Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study.

Placebo will be administered.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 5
Délai: Baseline up to Day 5

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline up to Day 5

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change from Baseline in MADRS Total Score to Day 2
Délai: Baseline up to Day 2

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline up to Day 2
Change from Baseline in Clinician Global Impression-Severity (CGI-S) Scale Score to Days 2 and 5
Délai: Baseline up to Day 2 and Day 5

The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher score indicating greater severity.

Baseline up to Day 2 and Day 5
Change from Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score to Day 5
Délai: Baseline up to Day 5

The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item is rated by the participant according to a 5-point Likert scale, where 0 denotes "Not at all" or "Never" and 4 denotes "Extremely" or "Always". Before summing the items to create a total score, item 11 and item 12 are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items, which range from 0 to 60. Higher score indicates more severe depressive symptomatology.

Baseline up to Day 5
Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scale Score to Day 5
Délai: Baseline up to Day 5

The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. GAD-7 has seven items, which measure frequency of various signs of GAD using a 4-point Likert scale (where, Not at all = 0, Several days = 1, More than half the days = 2, and Nearly every day = 3). The total score ranges from 0 to 21 with increasing scores indicative of greater severity of symptoms of anxiety. Severity of anxiety on the GAD-7 is rated as follows: none (0-4), mild (5-9), moderate (10-14) and severe (15-21).

Baseline up to Day 5
Number of Participants with Adverse Events (AEs)
Délai: Up to approximately 18 weeks

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to approximately 18 weeks
Number of Participants with Abnormalities in Vital Signs Parameters
Délai: Up to approximately 18 weeks

Participants with abnormalities in vital signs (supine blood pressure, pulse/heart rate, respiratory rate, oral temperature) parameters will be reported.

Up to approximately 18 weeks
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
Délai: Up to approximately 18 weeks

Participants with 12-lead ECG abnormalities will be reported.

Up to approximately 18 weeks
Number of Participants With Abnormalities in Laboratory Parameters
Délai: Up to approximately 18 weeks

Participants with abnormalities in clinical laboratory parameters (hematology and serum chemistry) will be reported.

Up to approximately 18 weeks
Number of Participants Reporting Changes in Weight/Body Mass Index (BMI)
Délai: Up to approximately 18 weeks

Participants with changes in weight/BMI will be reported.

Up to approximately 18 weeks
Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
Délai: Up to approximately 18 weeks

The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.

Up to approximately 18 weeks
Change from Baseline in Cognitive Functioning Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)
Délai: From Baseline up to 4 weeks

The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials.

From Baseline up to 4 weeks
Change from Baseline in Cognitive Functioning Measured by the Digit Symbol Substitution Test (DSST)
Délai: From Baseline up to 4 weeks

The DSST is recognized as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention. The DSST measures attention, working memory, sustained visual attention and psychomotor speed. Participants are given a table that pairs digits and symbols, and asked to decipher a code using the table, completing as many as possible in 90 seconds.

From Baseline up to 4 weeks
Plasma Concentrations of JNJ-89495120
Délai: Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

Plasma concentrations of JNJ-89495120 will be reported.

Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

26 décembre 2024

Achèvement primaire (Réel)

25 juin 2026

Achèvement de l'étude (Réel)

10 août 2026

Dates d'inscription aux études

Première soumission

15 janvier 2025

Première soumission répondant aux critères de contrôle qualité

15 janvier 2025

Première publication (Réel)

20 janvier 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

24 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 89495120MDD2001
  • 89495120MDD2001 (Autre identifiant: Janssen Research & Development, LLC)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner